AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Lutetium-177 prostate-specific membrane antigen radioligands (Lu-177-PSMA) are new therapeutic agents for the treatment of metastatic castration-resistant prostate cancer (mCRPC). We evaluated the prognostic value of circulating tumour DNA (ctDNA) profiling in patients with mCRPC starting treatment...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Vanwelkenhuyzen, Jan, Van Bos, Eva, Van Bruwaene, Siska, Lesage, Karl, Maes, Alex, Üstmert, Sezgin, Lavent, Filip, Beels, Laurence, Grönberg, Henrik, Ost, Piet, Lindberg, Johan, De Laere, Bram
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarker Cell-free DNA Circulating tumour DNA Liquid biopsy Lutetium-177-PSMA Medicine and Health Sciences Metastatic castration-resistant prostate cancer Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!